Archive for Evommune

Evommune Announces $125 Million Private Placement

February 17, 2026

Evommune’s Dupixent-like phase 2 eczema data drive 75% stock rally

February 11, 2026

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

February 10, 2026

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

December 11, 2025

Inflammation biotech Evommune heads to NYSE with $150M IPO

November 10, 2025

Evommune nabs $150M in IPO amid federal shutdown

November 10, 2025